Vera Therapeutics Inc Class A VERA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $45.66
- Day Range
- $42.38–46.12
- 52-Week Range
- $9.24–50.78
- Bid/Ask
- $43.10 / $43.55
- Market Cap
- $2.38 Bil
- Volume/Avg
- 691,938 / 535,801
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 72
- Website
- https://www.veratx.com
Comparables
Valuation
Metric
|
VERA
|
EXEL
|
ARVN
|
---|---|---|---|
Price/Earnings (Normalized) | — | 17.02 | — |
Price/Book Value | 7.26 | 3.49 | 2.83 |
Price/Sales | — | 3.97 | 11.73 |
Price/Cash Flow | — | 16.25 | — |
Price/Earnings
VERA
EXEL
ARVN
Financial Strength
Metric
|
VERA
|
EXEL
|
ARVN
|
---|---|---|---|
Quick Ratio | 20.98 | 4.05 | 3.57 |
Current Ratio | 21.43 | 4.27 | 3.62 |
Interest Coverage | −19.84 | — | — |
Quick Ratio
VERA
EXEL
ARVN
Profitability
Metric
|
VERA
|
EXEL
|
ARVN
|
---|---|---|---|
Return on Assets (Normalized) | −35.17% | 14.82% | −22.33% |
Return on Equity (Normalized) | −45.77% | 19.05% | −47.53% |
Return on Invested Capital (Normalized) | −40.21% | 14.99% | −54.26% |
Return on Assets
VERA
EXEL
ARVN
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Yvgvscmfx | Zfd | $531.4 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Wsysfwvc | Lcsnlnh | $119.5 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Wcxbhxsb | Jybxr | $114.9 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Cwtnvkxgm | Clgwf | $35.3 Bil | |||
argenx SE ADR
ARGX
| Rgqfbhkx | Cnx | $32.0 Bil | |||
BioNTech SE ADR
BNTX
| Sbvzxxf | Kdf | $28.1 Bil | |||
Moderna Inc
MRNA
| Mzkxjdhdf | Gfkx | $25.3 Bil | |||
United Therapeutics Corp
UTHR
| Hqwqrmbmk | Wmxs | $16.0 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Pvxxklxh | Shrnf | $13.4 Bil | |||
Incyte Corp
INCY
| Lvnwrpfm | Kcttlf | $12.7 Bil |